Evidence map›Paper›PMID 39867731›Full record

ArticleWorld journal of clinical oncology2025

Cohort study on the treatment of

Jiang-Yu Bian, Yu-Fang Feng, Wen-Ting He, Tong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. East meets West: The winning combination againstWorld journal of clinical oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiang-Yu BianDepartment of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China.
Yu-Fang FengDepartment of Oncology, The Fourth Clinical Medical College of Xinjiang Medical University, Urumqi‎ 830001, China.
Wen-Ting HeDepartment of Oncology, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi‎ 830001, China.
Tong ZhangDepartment of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China. ashtray7654@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with

aimTo evaluate the efficacy of integrated Chinese and Western medicine in the treatment of

methodsA cohort study was conducted on patients with

resultsA total of 34 cases were included, with 23 in Chinese-Western medicine cohort (cohort A) and 11 in Western medicine cohort (cohort B). The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B, with a statistically significant difference (

conclusionIntegrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with

Indexed as

BRAF V600E mutationCohort studyIntegrated Chinese and Western medicineMetastatic colorectal cancer

Identifiers

PMID39867731
PMCPMC11528896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.